SCHEMBL26739619

SCHEMBL26739619

CCC(=O)OCC(COC(=O)CC)CC(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.40
▸ TSHR P16473 3/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ NAAA Q02083 1/20 0.38
▸ CACNA2D1 P54289 2/20 0.36
▸ CACNB3 P54284 1/20 0.36
▸ CACNA1C Q13936 1/20 0.36
▸ PGR P06401 1/20 0.36
▸ ADRA1A P35348 1/20 0.36
▸ HTR2B P41595 1/20 0.36
▸ CACNA2D2 Q9NY47 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ BLM P54132 1/20 0.34
▸ WRN Q14191 1/20 0.34
▸ HIF1A Q16665 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28422860 0.83 NAAA (0.38) MAPTTSHRCYP3A4ATMTDP1
SCHEMBL22838023 0.83 MAPT (0.40) MAPTTSHRCYP3A4ATMTDP1
SCHEMBL124736 0.81 — —
SCHEMBL28015107 0.80 TSHR (0.44) MAPTTSHRCYP3A4ATMTDP1
SCHEMBL14191352 0.79 TSHR (0.52) MAPTTSHRCYP3A4ATMTDP1
SCHEMBL3628331 0.79 TSHR (0.52) MAPTTSHRCYP3A4ATMTDP1
SCHEMBL444679 0.79 — —
Hydrochloric Acid SCHEMBL27501013 0.79 TSHR (0.46) MAPTTSHRCYP3A4ATMTDP1
SCHEMBL28014440 0.79 TSHR (0.53) MAPTTSHRCYP3A4ATMTDP1
SCHEMBL28971810 0.78 TSHR (0.47) MAPTTSHRCYP3A4ATMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357207-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS BCP3 PTY LIMITED (AU) 2023-11-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357207-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS MUC1, MPO, SERPINB1 MAPT 2173/4885TSHR 1561/4885CYP3A4 2386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback